VISK Viskase Holdings, Inc.
Mergers ·
Enzon, which calls itself a public company acquisition vehicle, agreed on June 20, 2025 to merge with Viskase in an all-stock deal. Viskase holders would own about 84.1% of the combined company, and Enzon common holders about 2.06%. The 8-K and release give no Viskase revenue, debt or earnings.
We have not published a story on Viskase Holdings yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $26,000 | |
| Net income (loss) | -$3.4 million | $778,000 |
| Cash from operations | -$3.0 million | $1.1 million |
| Cash and equivalents | $9.2 million | $46.9 million |
Our latest story on this, dated Jun 23, 2025: "Enzon Pharmaceuticals (now Viskase Holdings) agrees all-stock merger with Viskase". The story links the filing or release it is based on. Read the story.
Viskase Holdings, Inc. trades under the ticker VISK on OTC.
Viskase Holdings, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Viskase Holdings, Inc. is 727510. Its filings are on SEC EDGAR.
14,331,620 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-03.
Our directory records Viskase Holdings, Inc. under United States.
Our directory classifies Viskase Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Viskase Holdings, Inc. is US2939048011.
aibio.space lists Viskase Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Viskase Holdings, Inc. reported a net loss of $3.4 million for the fiscal year ended Dec 31, 2025, and used $3.0 million of cash in operations, per its annual report to the SEC.
$7.9 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Viskase Holdings, dated Jun 23, 2025: "Enzon Pharmaceuticals (now Viskase Holdings) agrees all-stock merger with Viskase". Enzon, which calls itself a public company acquisition vehicle, agreed on June 20, 2025 to merge with Viskase in an all-stock deal. Viskase holders would own about 84.1% of the combined company, and Enzon common holders about 2.06%. The 8-K and release give no Viskase revenue, debt or earnings. Source.
We do not publish live share prices. In its annual report, Viskase Holdings, Inc. put the market value of shares held by non-affiliates (public float) at $4.9 million as of Jun 30, 2025.
SEC records list Viskase Holdings, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,5.01,5.02,5.03,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,5.03,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 425. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Offered to buy back its own securities. SEC Form SC TO-I. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio